A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure

Trial Profile

A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Latanoprost/netarsudil (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms Mercury 3
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Status changed from planning to recruiting.
    • 07 Mar 2017 According to an Aerie media release, this trial is expected to commence in mid-2017.
    • 28 Mar 2016 According to Aerie media release, this trial will facilitate regulatory approval and commercialization in Europe. This trial is expected to commence in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top